ClinicalTrials.gg
RecruitingNCT06639828Updated Nov 20, 2026

Phase 4 Paediatric Study to Evaluate Sonazoid Safety and Efficacy for Contrast-Enhanced Ultrasound Liver Imaging

A Phase 4 interventional study of Contrast-Enhanced Ultrasound in Focal Liver Lesions, sponsored by GE Healthcare. Recruiting at 6 sites in 3 countries. Open to participants aged Up to 18 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by GE Healthcare · Phase 4, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 10 months later.
Updated Nov 20, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
Up to 18 Years
Sex
All
01

Study summary

Liver tumours, 40% of which are benign, account for 1% to 4% of all solid tumours in children. The benign tumours are mainly haemangiomas, liver hamartomas, and liver cell adenomas. The malignant tumours are mainly hepatoblastoma, hepatocellular carcinoma (HCC), malignant liver mesothelioma, and rhabdomyosarcoma. The differential diagnosis of liver masses in children is generally based on the child's age, the clinical evaluation (including alpha-fetoprotein test results), and imaging characteristics.

Liver tumours seldom produce clear symptoms and signs in the early stages, and they progress rapidly. As a result, most liver tumours are not diagnosed until the middle or late stages. To improve survival among patients with liver tumours, clinicians must find the liver tumours as early as possible and determine whether the tumours are benign or malignant. Conventional ultrasonography is commonly used for screening, and is preferred as the first-line imaging technique for children. Not only does it have a wide range of applications and a high diagnostic yield, but it is well accepted by patients and their parents. It can be performed in the examination room with the parents present, allowing real-time imaging and direct interaction with patient and parents.

CEUS is a non-invasive imaging technology that can continuously and dynamically observe blood perfusion in tumours in real-time through injection of a contrast agent to enhance the blood flow reflux signal in the human body. Consequently, CEUS is useful for visualising capillaries and tissue perfusion in the human body.

The purpose of this current study is to evaluate the use of Sonazoid™ perfluorobutane (PFB) microbubbles as a contrast medium for CEUS for evaluation of solitary liver masses in children.

Read the detailed description

This Phase 4, open-label, non-randomised, multicentre prospective study in Europe will enrol paediatric patients who are presenting with ≥1 confirmed untreated target FLL. This study plans to enrol at least 50 subjects at up to 12 centres in Europe. If a patient has multiple FLLs, the Investigator must select the target lesion at their discretion. Where possible, the target lesion should be a clearly visible and accessible lesion that could be easily followed during the non-CE ultrasound examination and all phases of the CEUS examination. The reference diagnosis/standard of truth for the target lesion of interest will be established by the principal investigators/sub-investigators on the basis of all available clinical information, including the results of biopsy, if available, and the dynamic CECT or CEMRI examination required for the study.

Following unenhanced (pre-contrast) ultrasound imaging of the target FLL, a single dose of Sonazoid™, dosed according to body weight (0.12 μL microbubbles/kg), will be intravenously administered to each patient, and a CEUS examination will be performed, with images acquired as specified in the Imaging Manual.

The unenhanced ultrasound and CEUS images will be assessed by 3 independent blinded readers following WFUMB-EFSUMB guidelines for adults, and in accordance with the Independent Review Charter. The diagnoses based on the unenhanced ultrasound and the CEUS results will be compared with the reference diagnosis/standard of truth for the target lesion. The diagnostic accuracy, sensitivity and specificity of the unenhanced ultrasound and CEUS images will then be calculated. Clinical safety data will be collected throughout the study. Safety will be evaluated by monitoring subjects for the occurrence of AEs.

02

Conditions studied

  • Focal Liver Lesions

Keywords

  • Contrast-Enhanced Ultrasound
03

In context

Lead sponsor

GE Healthcare is the lead sponsor of 176 studies on the registry; 21 are open to participants now.

Of its 19 completed or terminated interventional studies of FDA-regulated products, 16 (84%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subject is \<18 years of age on the day of consent.
  • The subject has at least 1 untreated FLL with ≤8 lesions (excluding cysts), with ≤8 cm confirmed in a diagnostic examination performed in the past month (or past 3 months if the lesion was benign) and that could also be visualised when obtained via unenhanced ultrasound imaging
  • The subject has had a dynamic CECT or CEMRI examination within the past month or is scheduled to have one in the month following inclusion in the study, and these images are/would be available.
  • The subject can comply with study procedures.
  • Parents or legally authorised representatives have signed the Form approved for this study by the Independent Review Board (IRB)/Independent Ethics Committee (IEC). The form will indicate that the patient (and/or a legally acceptable representative) has been informed of all pertinent aspects of the study. Patients who are able to provide assent have signed an age-appropriate paediatric assent form
  • Post-menarcheal female patients must have a negative urine pregnancy test at screening and at pre-dose on the dosing day.
  • Post-menarcheal female patients and male patients who are sexually active with a partner of must be practicing abstinence or be using an effective form of (See Section 8.6) for ≥30 days before being enrolled in the study
  • The subject has a body weight of 3 kg or greater.
  • The subject has a negative egg allergy test if the egg allergy status of the subject is unknown.

Exclusion criteria

Exclusion Criteria:

  • The subject has a known or suspected to any of the components of Sonazoid™, including a history of allergies to eggs or egg products (i.e., manifested by full body rash, respiratory difficulty, oral or laryngeal swelling, hypotension, or shock).
  • The subject has an acute clinically fatal condition (i.e., the expected survival is ≤6 months).
  • The subject has previously received Sonazoid™ or another ultrasound contrast agent within the past 30 days.
  • The subject had undergone or is planning to undergo an examination with a contrast agent (i.e., iodinated x-ray contrast agent, MRI contrast agent or another ultrasound contrast agent) within the 24 hours before or after Sonazoid™ injection.
  • The subject has undergone or was undergoing systemic or loco-regional chemotherapy or radiation therapy
  • The subject is participating in another clinical trial with an unregistered medicinal product, or less than 30 days has passed since the subject completed participation in such a trial
  • The subject is a pregnant or lactating female.
  • The physician judges that a large-enough needle (24-gauge or larger) cannot be inserted.
  • The subject has a known right-left cardiac shunt.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Sonazoid

    Participants will receive a single iv dose of Sonazoid™, dosed according to body weight (0.12 μL microbubbles/kg)

    Diagnostic Test: Contrast-Enhanced Ultrasound

Interventions

  • Diagnostic testContrast-Enhanced Ultrasound

    Following unenhanced (pre-contrast) ultrasound imaging of the target focal liver lesions (FLL), Sonazoid™ will be intravenously administered and a contrast-enhanced examination will be performed.

06

What researchers measure

Primary outcomes

  1. Accuracy of Sonazoid-enhanced ultrasound at imaging focal liver lesions during the vascular phase of imaging

    Accuracy of the diagnosis based on the independent blinded read of the Sonazoid™-enhanced imaging for lesion differentiation (benign or malignant FLLs) during vascular phase imaging. The WFUMB-EFSUMB guidelines for interpreting CEUS of the liver in adults shall be used for interpreting the images and the subject's baseline diagnosis (well-established by CECT, CEMRI or biopsy) will be used as the reference diagnosis/standard of truth.

    Time frame: Images to be captured during the studies CEUS examination [approximately 5 seconds prior to bolus injection, up to 4-minutes post injection for the vascular phase] and blinded image evaluations shall be executed remotely at a central lab

  2. Sensitivity of Sonazoid-enhanced ultrasound at imaging focal liver lesions during the vascular phase of imaging

    Sensitivity of the diagnosis based on the independent blinded read of the Sonazoid™-enhanced imaging for lesion differentiation (benign or malignant FLLs) during vascular phase imaging. The WFUMB-EFSUMB guidelines for interpreting CEUS of the liver in adults shall be used for interpreting the images and the subject's baseline diagnosis (well-established by CECT, CEMRI or biopsy) will be used as the reference diagnosis/standard of truth.

    Time frame: Images to be captured during the studies CEUS examination [approximately 5 seconds prior to bolus injection, up to 4-minutes post injection for the vascular phase] and blinded image evaluations shall be executed remotely at a central lab

  3. Specificity of Sonazoid-enhanced ultrasound at imaging focal liver lesions during the vascular phase of imaging

    Specificity of the diagnosis based on the independent blinded read of the Sonazoid™-enhanced imaging for lesion differentiation (benign or malignant FLLs) during vascular phase imaging. The WFUMB-EFSUMB guidelines for interpreting CEUS of the liver in adults shall be used for interpreting the images and the subject's baseline diagnosis (well-established by CECT, CEMRI or biopsy) will be used as the reference diagnosis/standard of truth.

    Time frame: Images to be captured during the studies CEUS examination [approximately 5 seconds prior to bolus injection, up to 4-minutes post injection for the vascular phase] and blinded image evaluations shall be executed remotely at a central lab

Secondary outcomes

  1. Comparison of accuracy of Sonazoid-enhanced ultrasound to Unenhanced ultrasound at imaging focal liver lesions during vascular phase

    Accuracy of the diagnosis (benign or malignant FLL) based on the Sonazoid™-enhanced imaging by vascular phase imaging, as compared with the unenhanced ultrasound imaging, when the baseline diagnosis is used as the reference standard.

    Time frame: Images to be captured during the studies CEUS examination [approximately 5 seconds prior to bolus injection, up to 4-minutes post injection for the vascular phase] and blinded image evaluations shall be executed remotely at a central lab.

  2. Comparison of accuracy of Sonazoid-enhanced ultrasound to Unenhanced ultrasound at imaging focal liver lesions during vascular and Kupffer phase

    Accuracy of the diagnosis (benign or malignant FLL) based on the Sonazoid™-enhanced imaging by vascular phase and Kupffer phase imaging, as compared with the unenhanced ultrasound imaging, when the baseline diagnosis is used as the reference standard.

    Time frame: Images to be captured during the studies CEUS examination [approximately 5 seconds prior to bolus injection, up to 10-minutes post injection for the vascular and Kupffer phase(s)] and blinded image evaluations shall be executed remotely at a central lab

  3. Comparison of sensitivity of Sonazoid-enhanced ultrasound to Unenhanced ultrasound at imaging focal liver lesions during vascular phase

    Sensitivity of the diagnosis (benign or malignant FLL) based on the Sonazoid™-enhanced imaging by vascular phase imaging, as compared with the unenhanced ultrasound imaging, when the baseline diagnosis is used as the reference standard.

    Time frame: Images to be captured during the studies CEUS examination [approximately 5 seconds prior to bolus injection, up to 4-minutes post injection for the vascular phase] and blinded image evaluations shall be executed remotely at a central lab.

  4. Comparison of sensitivity of Sonazoid-enhanced ultrasound to Unenhanced ultrasound at imaging focal liver lesions during vascular and Kupffer phase

    Sensitivity of the diagnosis (benign or malignant FLL) based on the Sonazoid™-enhanced imaging by vascular phase and Kupffer phase imaging, as compared with the unenhanced ultrasound imaging, when the baseline diagnosis is used as the reference standard.

    Time frame: Images to be captured during the studies CEUS examination [approximately 5 seconds prior to bolus injection, up to 10-minutes post injection for the vascular and Kupffer phase(s)] and blinded image evaluations shall be executed remotely at a central lab

  5. Comparison of specificity of Sonazoid-enhanced ultrasound to Unenhanced ultrasound at imaging focal liver lesions during vascular phase

    Specificity of the diagnosis (benign or malignant FLL) based on the Sonazoid™-enhanced imaging by vascular phase imaging, as compared with the unenhanced ultrasound imaging, when the baseline diagnosis is used as the reference standard.

    Time frame: Images to be captured during the studies CEUS examination [approximately 5 seconds prior to bolus injection, up to 4-minutes post injection for the vascular phase] and blinded image evaluations shall be executed remotely at a central lab.

  6. Comparison of specificity of Sonazoid-enhanced ultrasound to Unenhanced ultrasound at imaging focal liver lesions during vascular and Kupffer phase

    Specificity of the diagnosis (benign or malignant FLL) based on the Sonazoid™-enhanced imaging by vascular phase and Kupffer phase imaging, as compared with the unenhanced ultrasound imaging, when the baseline diagnosis is used as the reference standard.

    Time frame: Images to be captured during the studies CEUS examination [approximately 5 seconds prior to bolus injection, up to 10-minutes post injection for the vascular and Kupffer phase(s)] and blinded image evaluations shall be executed remotely at a central lab

  7. Comparison of diagnostic confidence of Sonazoid-enhanced ultrasound to Unenhanced ultrasound at imaging focal liver lesions during vascular phase

    The difference in the diagnostic confidence for the unenhanced ultrasound imaging and that for the Sonazoid™-enhanced ultrasound imaging based on the vascular phase. The difference in the diagnostic confidence will ranged from -3 to 3, higher scores mean better outcome.

    Time frame: Images to be captured during the studies CEUS examination [approximately 5 seconds prior to bolus injection, up to 4-minutes post injection for the vascular phase] and blinded image evaluations shall be executed remotely at a central lab.

  8. Safety of Sonazoid following intravenous administration of IMP in paediatric patients based on Treatment-emergent adverse events

    Number and percentage of subjects with Treatment-emergent adverse events, defined as adverse events that occurred at any timepoint from the administration of Sonazoid™ to the end of the study (72 hours after Sonazoid™ administration)

    Time frame: From administration of Sonazoid, up to 4 hours for in-person monitoring followed by 24-hour and 72-hour telephone follow ups

  9. Safety of Sonazoid following intravenous administration of IMP in paediatric patients based on drug-related Treatment-emergent adverse events

    Number and percentage of subjects with drug-related Treatment-emergent adverse events

    Time frame: From administration of Sonazoid, up to 4 hours for in-person monitoring followed by 24-hour and 72-hour telephone follow ups

  10. Safety of Sonazoid following intravenous administration of IMP in paediatric patients based on Treatment-emergent Serious Adverse events

    Number and percentage of subjects with Treatment-emergent Serious Adverse events

    Time frame: From administration of Sonazoid, up to 4 hours for in-person monitoring followed by 24-hour and 72-hour telephone follow ups

  11. Safety of Sonazoid following intravenous administration of IMP in paediatric patients based on Physical examination

    Number and percentage of subjects with changes in physical examination status (normal/abnormal)

    Time frame: Pre-administration of Sonazoid and 4 hours post administration

  12. Safety of Sonazoid following intravenous administration of IMP in paediatric patients based on Vital signs

    Summary statistics of systolic/diastolic blood pressure, heart rate, respiratory rate, body temperature, and oxygen saturation for each timepoint

    Time frame: Pre-administration of Sonazoid and 4 hours post administration

  13. Safety of Sonazoid following intravenous administration of IMP in paediatric patients based on Clinical laboratory results

    Summary statistics of clinical laboratory for each timepoint

    Time frame: Pre-administration of Sonazoid and 4 hours post administration

07

Study locations

3 of 6 sites recruiting
  • Munich University Hospital
    München, 81377, Germany
    Not yet recruiting
  • Papa Giovanni XXIII Hospital
    Bergamo, 24127, Italy
    Not yet recruiting
  • Giannina Gaslini Institute
    Genoa, 16147, Italy
    Not yet recruiting
  • University Hospitals Bristol and Weston NHS Foundation Trust
    Bristol, BS2 8BJ, United Kingdom
    Recruiting
  • King's College Hospital NHS Foundation Trust
    London, SE5 9RS, United Kingdom
    Recruiting
  • Imperial College Healthcare NHS Trust
    London, W2 1NY, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jan 2025 (actual). Primary completion is estimated for Nov 2027, 33 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 20, 2026: primary completion Jul 2026 → Nov 2027 and completion Oct 2026 → Nov 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2024
First posted
Oct 15, 2024
StartActual
Jan 20, 2025
Primary completionEst.
Nov 1, 2027was Jul 2026
CompletionEst.
Nov 1, 2027was Oct 2026
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jul 31, 2026→Nov 1, 2027
Nov 20, 2026
Study completion
Oct 31, 2026→Nov 1, 2027
Nov 20, 2026
Contact
Study contact changed: d•••@gehealthcare.com · •••7614→Y•••@gehealthcare.com · •••3986. See the current contact
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Primary completion Jul 31, 2026→Nov 1, 2027
    Study completion Oct 31, 2026→Nov 1, 2027
    Contact Study contact changed: d•••@gehealthcare.com · •••7614→Y•••@gehealthcare.com · •••3986. See the current contact
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06639828
Lead sponsor
GE Healthcare
Collaborators
PPD Development, LP, Medidata Solutions
Responsible party
Sponsor
First posted
Oct 15, 2024
Start date
Jan 20, 2025
Primary completion
Nov 1, 2027 (estimated)
Completion
Nov 1, 2027 (estimated)
Last update
Nov 20, 2026

Study contacts

Tingting Wang
Contact
Tingting.Wang12@gehealthcare.com
+86 21 3895 4500
Yongqing Tang, MD
Contact
Yongqing.Tang@gehealthcare.com
+86 189 1820 3986
Yongqing Tang
study director · GE Healthcare

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion